Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH,
enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as
antithrombotic therapy for patients in atrial fibrillation undergoing transesophageal
echocardiography (TEE) guided chemical or electrical cardioversion to sinus rhythm.
HYPOTHESIS: Early cardioversion from atrial fibrillation can be safely performed using a
short-term anticoagulation strategy of low molecular weight heparin (Lovenox, Sanofi-Aventis)
compared to unfractionated heparin, accompanied by a TEE examination prior to cardioversion.
The use of LMWH with TEE will result in a safe, cost-effective, and possible efficacious
approach to cardioversion of atrial fibrillation compared to UFH with TEE.